Cabot (NYSE:CBT) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.

Several other analysts have also weighed in on CBT. SunTrust Banks raised Cabot from a “hold” rating to a “buy” rating in a report on Tuesday, December 19th. Loop Capital raised Cabot from a “hold” rating to a “buy” rating and set a $82.00 price objective on the stock in a report on Friday, January 5th. Zacks Investment Research raised Cabot from a “hold” rating to a “buy” rating and set a $75.00 price objective on the stock in a report on Wednesday, January 17th. Jefferies Group reaffirmed a “buy” rating and issued a $78.00 price target on shares of Cabot in a research note on Thursday, February 8th. Finally, Northcoast Research set a $75.00 price target on Cabot and gave the company a “buy” rating in a research note on Monday, February 12th. Five research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $72.29.

How to Become a New Pot Stock Millionaire

Shares of Cabot (NYSE:CBT) opened at $58.94 on Tuesday. Cabot has a fifty-two week low of $50.21 and a fifty-two week high of $68.63. The firm has a market capitalization of $3,657.13, a P/E ratio of 60.14, a PEG ratio of 1.46 and a beta of 1.31. The company has a current ratio of 1.63, a quick ratio of 1.02 and a debt-to-equity ratio of 0.43.

Cabot (NYSE:CBT) last announced its quarterly earnings data on Tuesday, February 6th. The specialty chemicals company reported $0.93 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.78 by $0.15. Cabot had a return on equity of 15.01% and a net margin of 2.30%. The company had revenue of $720.00 million for the quarter, compared to analyst estimates of $653.54 million. During the same quarter last year, the firm earned $0.84 EPS. Cabot’s revenue for the quarter was up 17.8% compared to the same quarter last year. research analysts expect that Cabot will post 4.06 earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in CBT. Bank of New York Mellon Corp boosted its stake in Cabot by 113.6% in the 4th quarter. Bank of New York Mellon Corp now owns 1,978,158 shares of the specialty chemicals company’s stock valued at $121,834,000 after buying an additional 1,052,224 shares in the last quarter. Two Sigma Advisers LP boosted its stake in Cabot by 474.2% in the 4th quarter. Two Sigma Advisers LP now owns 420,052 shares of the specialty chemicals company’s stock valued at $25,871,000 after buying an additional 346,900 shares in the last quarter. Two Sigma Investments LP boosted its stake in Cabot by 302.7% in the 4th quarter. Two Sigma Investments LP now owns 279,982 shares of the specialty chemicals company’s stock valued at $17,244,000 after buying an additional 210,457 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Cabot by 97.9% in the 4th quarter. Renaissance Technologies LLC now owns 418,000 shares of the specialty chemicals company’s stock valued at $25,745,000 after buying an additional 206,800 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. boosted its stake in Cabot by 9.4% in the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 1,780,692 shares of the specialty chemicals company’s stock valued at $99,363,000 after buying an additional 152,988 shares in the last quarter. 87.18% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “ValuEngine Downgrades Cabot (CBT) to Hold” was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.watchlistnews.com/valuengine-downgrades-cabot-cbt-to-hold/1954828.html.

Cabot Company Profile

Cabot Corporation is a global specialty chemicals and performance materials company. The Company operates through four business segments: reinforcement materials, performance chemicals, purification solutions and specialty fluids. Reinforcement materials’ rubber grade carbon blacks are used to enhance the physical properties of the systems and applications in which they are incorporated.

Analyst Recommendations for Cabot (NYSE:CBT)

Receive News & Ratings for Cabot Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabot and related companies with MarketBeat.com's FREE daily email newsletter.